ALK (C1156Y)

ALK · Variant type: point · HGVS: p.C1156Y

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Lorlatinib	100.0%	0.0%	97.24
2	Gilteritinib	100.0%	0.0%	88.97
3	Repotrectinib	99.9%	0.1%	84.21
4	Entrectinib	99.7%	0.3%	93.69
5	Alectinib	99.2%	0.8%	95.49
6	Sunitinib	98.2%	1.8%	91.73
7	Ceritinib	98.0%	2.0%	95.44
8	Alpelisib	97.3%	2.7%	97.22
9	Crizotinib	97.3%	2.7%	91.39
10	Pralsetinib	97.0%	3.0%	93.43
11	Brigatinib	95.6%	4.4%	82.96
12	Ruxolitinib	94.1%	5.9%	98.25
13	Nintedanib	91.7%	8.3%	90.23
14	Baricitinib	88.6%	11.4%	97.99
15	Pacritinib	86.9%	13.1%	88.64
16	Bosutinib	85.4%	14.6%	87.22
17	Osimertinib	82.0%	18.0%	97.24
18	Tenalisib	79.5%	20.5%	97.98
19	Lazertinib	76.9%	23.1%	97.47
20	Tepotinib	70.2%	29.8%	99.75
21	Fedratinib	65.0%	35.0%	96.21
22	Fostamatinib	61.2%	38.8%	96.74
23	Darovasertib	54.1%	45.9%	96.99
24	Defactinib	51.6%	48.4%	92.68
25	Upadacitinib	51.2%	48.8%	97.98

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Lorlatinib	100.0%	97.2%	+2.8%
Gilteritinib	100.0%	99.5%	+0.5%
Repotrectinib	99.9%	99.4%	+0.6%
Entrectinib	99.7%	98.8%	+0.9%
Alectinib	99.2%	98.6%	+0.7%
Sunitinib	98.2%	87.7%	+10.5%
Ceritinib	98.0%	98.3%	-0.2%
Alpelisib	97.3%	80.7%	+16.7%
Crizotinib	97.3%	97.7%	-0.4%
Pralsetinib	97.0%	82.6%	+14.4%
Brigatinib	95.6%	99.2%	-3.6%
Ruxolitinib	94.1%	52.1%	+42.1%
Nintedanib	91.7%	84.9%	+6.8%
Baricitinib	88.6%	46.4%	+42.3%
Pacritinib	86.9%	55.3%	+31.7%
Bosutinib	85.4%	75.1%	+10.3%
Osimertinib	82.0%	80.5%	+1.5%
Tenalisib	79.5%	45.2%	+34.3%
Lazertinib	76.9%	46.3%	+30.7%
Tepotinib	70.2%	—	—
Fedratinib	65.0%	—	—
Fostamatinib	61.2%	—	—
Darovasertib	54.1%	—	—
Defactinib	51.6%	—	—
Upadacitinib	51.2%	—	—

Cancer	Organ	Source
carcinoma_lung	Lung	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.3ms